Thank You! Your Ebook Is READY!

We've emailed you a link to download your eBook “The Complete Guide to Identifying Record-Breaking Trades." You can also scroll to the bottom of this page to click to download straight from here.

P.S. I just published my latest white-paper that I'd like to share with you...it's below, and it's eye opening.

Insert Content Template or Symbol
The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

We've emailed you a link to download your eBook “The Complete Guide to Identifying Record-Breaking Trades." You can also scroll to the bottom of this page to click to download straight from here.

P.S. I just published my latest white-paper that I'd like to share with you...it's below, and it's eye opening.

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

We've emailed you a link to download your eBook “The Complete Guide to Identifying Record-Breaking Trades." You can also scroll to the bottom of this page to click to download straight from here.

P.S. I just published my latest white-paper that I'd like to share with you...it's below, and it's eye opening.


Why Opioids are Going Away
And The Company Replacing Them
 
J. Daryl Thompson  


Why Opioids are Going Away
And The Company Replacing Them
 
J. Daryl Thompson  


Why Opioids are Going Away
And The Company Replacing Them
 
J. Daryl Thompson  

Why are Opioids At risk?

Society has reached a breaking point with the catastrophic effects caused by opioids, and the government has recently acted in an attempt to curb the epidemic. These actions are similar to those of the D.A.R.E. campaign back in the 80s and 90s, except this time it’s combating prescription drugs instead of illicit ones. There’s a big difference here; illicit drugs can’t be regulated, but prescription drugs can.

That means the crackdown isn’t on society as a whole, but it is being implemented on pharmaceutical companies and doctors. Both are scrambling to find a replacement for highly addictive opiates and one new biotech may just be flying under the radar, making its way through clinical trials with the solution.

Vitality Biopharma (OTCQB: VBIO) is on the verge of creating the next generation of chronic pain management drugs, an almost $83 billion market. (1)

How They Do It

Vitality Biopharma (OTCQB: VBIO) has harnessed the therapeutic abilities of cannabinoids derived from marijuana, with its proprietary prodrugs, providing patients with not just pain management, but also treating a wide range of other illnesses. With its proprietary formulations, VBIO has created an entirely new class of cannabinoid (CBD) glycosides, called “cannabosides.” CBD is a naturally occurring compound in marijuana with proven anti-inflammatory, antioxidant, and calming effects, among several other medical benefits.

VBIO is steadily proving CBD to be a game-changing drug throughout ongoing FDA trials—And they’ve came up with their own proprietary formulation that preserves all the beneficial aspects of CBD, without the side-effects of “getting high".

VBIO is a micro-cap CBD pharmaceutical company that sports all of the markings of a blockbuster biotech. Vitality’s pipeline is loaded and their most recent top performers, VB100 and VB210 have already passed a major hurdle in receiving FDA approval during preclinical studies. VBIO has also received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel, which permits the company to scale up activities at its facilities developing novel cannabinoid pharmaceutical prodrugs. This begins the regulatory approval phase for the first-in-man clinical trials this year, allowing VBIO to proceed through their final phase and get to market.

Simply put, the government is no longer holding VBIO back from providing relief to an array of illnesses.

Opiates Are The Past, Cannabinoids Are The Future

CBD has completely changed big pharma’s R&D’s focus the last few years when it comes to pain management. Recently, there has been a huge push in the pharmacological world to address and find a solution to the opioid crisis.

Currently, the industry has been able to do so with a few CBD formulations, but with limited success. To date, there are three cannabinoid products approved by the U.S. to unlock the therapeutic potential of marijuana, yet IMS health estimates sales have only reached $133 million in 2014, and they haven’t grown much since. So, what’s causing such a lag in sales for these products?

Sales are being suppressed by several things like poor oral bioavailability, irregular metabolism, inconvenient administration, short active response, poor tolerability, and in some cases, psychoactive side effects. In short, these companies weren’t able to formulate their drugs in a way that enabled them to release enough active ingredient (CBD), to be effective or administered through realistic daily-living methods.

VBIO has overcome these challenges with their proprietary cannabosides, developed through modifying CBD by enzymatic glycosylation. These IP-protected compounds tack on glucose to cannabinoids, making them water soluble. VBIO’s prodrugs make their way through the GI tract into the colon, where they are released. These agents coat and cool the intestine, providing pain relief, and relief of inflammation for patients, while limiting the amount of THC released into the bloodstream and brain. This targeted therapy greatly increases the efficacy and efficiency of CBD, maximizing their their deliverability to the mechanism of action,, while eliminating its psychoactive ability.

Vitality’s cannaboside drugs have shown to be nearly 10 times as potent as morphine for neuropathic pain relief, and non addictive. Studies have shown that they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. These and other revelations are the reason why VBIO’s proprietary cannaboside drug therapies are the next generation of chronic pain management. 

Big Pharma Shutting The Doors On Opioids

Sweeping regulations this summer caused Purdue Pharma, the biggest opioid producer on the market, to lay off most of its sales force(2) for OxyContin and is steadily downsizing operations. This immediately created an opportunity for R&D teams across the world to find a replacement. With big pharma jumping into the game so late, the answer, like so often in the medical world, probably lies in the hands of a new biotech or pharma startup. Which isn’t that surprising, as startups account for 63% (3) of worldwide prescription drugs currently on the market.

More than 2.4 million Americans suffer from a severe opioid use disorder, which includes dependence on heroin or a prescription opiate drugs. Opioids are involved in 61% of all overdoses across the county and the most recent data from the CDC reports more than 42,000 American deaths (4) occur each year due to opioid overdose.

Given these statistics and seeing no end in sight to the opioid epidemic, it’s no wonder that increased regulations and new oversight protocols are being enforced throughout the country. Certainly, big pharma wasn’t going to, provided prescriptions for painkillers have steadily increased the last 50 years and are a crucial aspect of taking care of our aging population. Because of this increase and the presumed need for these medications, Pharma wasn’t ready for the type of crackdown brought down by the Trump administration. And, following Purdue Pharma’s most recent actions, the industry is starting to talk, asking when alternatives like AbbVie Inc.’s VicodinÒ and Endo International’s PercocetÒ are going to be the next to transition themselves off the opioid market. The fact their time is coming sooner than later is the most likely scenario, provided how far these companies have distanced themselves from their own opioid products.

 SO Much Bigger Than Chronic Pain Management

Vitality Biopharma (VBIO) is setting itself up to be the market leader with its own new proprietary class of prodrugs, producing something truly new and innovative for a long range of

illnesses and pain management—something that is bound to totally change the medical world and offer major new solutions for a market in need. With its DEA approval and clinical trials in place, VBIO is ahead of the competitive curve and set to deliver what society has been so eagerly awaiting.

Beyond pain management, VBIO has also shown the ability to treat neurological and inflammatory disorders. The greatest potential, coming from their most recent clinical trials, has provided data showing positive results for patients suffering from the side effects from therapies like inflammatory bowel disease (IBD) & narcotic bowel syndrome (NBS).

Vitality is continuing to see strong efficacy in preclinical results for these “gut-targeted” treatments. In fact, VBIO’s treatment was able to reduce weight loss, damage to the colon, and largely improve gastrointestinal health compared to placebo controls.

Furthermore, the antimicrobial activity that has been demonstrated over time during tests of VBIO's therapies has been found to be so positive that the company has gone as far as filing for patent protection on the use of CBD-derived compounds for the treatment of microbe, including Clostridium difficile and other "superbug" pathogens.

And get this: at the top of the CDC's list is none other than Clostridium difficile (C. diff), which is classified as “an urgent threat to human health.” Why is that so important? Vitality has already

demonstrated antimicrobial reactivity of CBD derivatives against C. diff, and is conducting follow-on studies designed to enable pharmaceutical use of their targeted cannabinoid prodrugs for this application.

Studies conducted by VBIO have also shown that its prodrug inhibits colon cancer cell line growth at concentrations that are similar to those used by conventional chemotherapeutics. In the United States in 2017, the American Cancer Society estimated that 50,260 deaths occurred due to colorectal cancer, making it the third-leading cause of cancer-related death for women, and the second-leading cause of cancer-related death for men. If VB100 or 210 is approved to treat colon cancer following their current Phase II trials, this is a huge opportunity for investors.

VBIO’s pipeline is one of the most robust the industry has seen a quite some time, returning positive data for so many applications during FDA trials. Another application that’s recently been tested is VBIO’s proprietary cannabidiol and endocannabinoids, involved in key aspects of neuroprotection and remyelination, a regenerative process in the brain. Vitality’s cannabinoids have shown to be protective of oligodendrocyte progenitor cells, which show to be critical for brain repair in multiple sclerosis (MS). Clinical trial designs are beginning to include cannabosides in combination with approved drugs in order to reverse neurological damage caused by MS.


 Importance of Intellectual Property (IP)

Based on these and other positive results, VBIO is actually seeking broad intellectual property coverage against these pathogens through 2035. This allows VBIO to attain composition of 

matter claims for prodrugs of THC, CBD, and CBDV, protecting their intellectual property for every significant CBD pharmaceutical in their pipeline.

While we are still on the heels of everyone talking about GW Pharma and how their stock raised from $8/share to $164/share during clinical trials, VBIO is actually in a much stronger position to profit over the long term. Credit to GW Pharma is certainly due; after all, they were the first to gain DEA and FDA approval for their own CBD based drug Epidiolex, which has shown to greatly reduce seizures for patients suffering from epilepsy.

However, GW Pharma may have been in a rush by not obtaining their own IP rights for Epidiolex. GW Pharma is currently the biggest market-cap CBD pharma company, but it’s border-line shocking that it doesn’t even own its compounds! This makes them susceptible to any copy-cat company that is looking to piggy-back off their research and future medicine advancements.

Very few cannabinoid pharma companies are ever going to hold cannabinoid intellectual property, simply because you cannot protect IP for naturally-occurring substances. That’s what makes VBIO so unique and such an incredible investment opportunity. They own all their own compounds and have protected their own IP. They have designed a new class of drugs called cannabosides, and they own all the ‘composition of matter’ behind it.

With everything going for this young biotech startup, VBIO is not satisfied with its recent successes.

Even as news broke of its positive results from Phase I clinical trials and progressing to Phase II, VBIO had simultaneously created more than 200 other cannabinoid compounds and have patent claims for 79 of them!


Investing in VBIO now could be bigger than investing in GW Pharmaceuticals five years ago. At that time, during Phase I and II trials, Epidiolex was showing its ability to reduce seizures for patients suffering from epilepsy. As the first companies to successfully conduct CBD/THC FDA trials with such strong results, both GW Pharma and VBIO are setting themselves up to change the industry for years to come.

A key difference is that VBIO is just about to enter Phase II clinical trials... which is the same stage in which GW Pharma’s stock price skyrocketed.

 How Big Can VBIO Go

This is not one of those pipe-dream “clinical trial Phase I” stock; Vitality (OTCQB:VBIO) is a serious pharmaceutical company. VBIO presents what just might be an investment opportunity of a lifetime. VBIO prodrugs not only have the potential to be a part of the solution to solving the opioid epidemic with safe, effective, and non-addictive pain-relief, but they are also showing industry-changing results treating other major illnesses in clinical trials.

Considering the range of illnesses for which VB100 & VB210 may provide effective treatment (including IBD, MS and pain management markets), there is HUGE potential that VBIO could become a $1 billion company in short

time. IBD treatments on the global market are over $6.7 billion per year and growing (5), multiple sclerosis treatments are expected to reach $24 billion per year by 2024 (6), and global opioid sales reaching $23 billion per year (7). This makes for more than a $50 billion opportunity for VBIO. It could provide major revenues for VBIO if they only capture a fragment of these potential markets.

With rising forecasts for the need for painkillers to treat a range of chronic pain issues such as those arising from illnesses like cancer, arthritis and post-surgical operations, painkillers aren’t leaving the market anytime soon. In fact, they’re growing. When the most utilized and known pharma solutions like Purdue Pharma’s OxyContin is showing gaping chips in its armor, doctors and governments are seeking other options in pain management.  

VBIO is taking advantage of its own new proprietary delivery class of prodrugs, producing something truly new and innovative for a long range of illnesses and pain management. This is something that is bound to totally change the medical world and offer major new solutions for a market in need. With its DEA approval and clinical trials in place, VBIO is ahead of the competitive curve and set to deliver what society has been so eagerly awaiting.

How can I be so sure of this? 

 The 10 KEYS for Profitable Pharmaceutical & Biotech Investments

Since the biggest gains have already been made with companies like GW Pharma, I’ve been searching for my next record-breaking medical stock. Throughout my 25-year career of researching and investing, I’ve developed a checklist of qualities I identify in companies EVERY TIME before putting my hard-earned cash behind them. Call it sweat equity if you will, because this system requires a lot of research and time to track the development of potential investment opportunities and how to properly analyze how a company’s pipeline is progressing. 

In order to help others gain this big-picture perspective, I’ve distilled my system and call it the 10 KEYS for Profitable Pharmaceutical & Biotech Investments. I fully cover each of the 10 KEYS in my new ebook.

When applying these 10 KEYS, I immediately knew GW Pharma had discovered a drug with huge market potential. But honestly, this wasn’t rocket science, because medical researchers had known for decades that CBD could be an effective treatment for seizures. However, what was vitally important for me was the timing of my investment and knowing when to divest some of my investment. In the case of GW Pharma, discovering their ceiling had a lot to do with the imprudence on their part of not obtaining IP for their groundbreaking formulations. This decision, like so many other examples, came about by applying the 10-KEYS that have helped me establish a long-term career investing in the stock market, specifically in the pharma/biotech niche. If you’re considering investing in any stock falling within this niche, it is essential that you understand just how important these 10 KEYS are. Frankly, you might know some of the KEYS, but do you have a system to streamline your decision-making strategy?

I’ve spent so much time introducing VBIO and describing just how much incredible potential this company has, simply because they are positioning themselves to corner the market with IP-protected formulations of CBD that also eliminate its psychoactive ability. For years to come, big pharma and blue-chip biotech’s entering the CBD market will most likely have to pay significant royalties or include VBIO in their research in order to produce their own. This is just one of the keys, but it alone can ensure immediate investing gains if timed right and certainty lock in long-term profit.

With the current state of the biotech market, it’s important for investors to familiarize themselves with VBIO right now. I encourage you to read their regulatory filings, press releases and current 2018 prospectus, and you’ll learn what I’ve been researching over the last several weeks.

Apply the 10 KEYS not just to VBIO, but to any pharma/biotech stock you’ve been tracking and you will be ahead of so many others who are about to rush into the market.

The biotech industry has already shown that a massive bull run is underway. What was hype and speculation only a few years ago is now an increasingly investable market with tremendous upside. The future profit center for investors in this industry will be biopharma R&D that is pioneered by companies with proprietary technology and the intellectual property leading to exciting medical breakthroughs. Vitality Biopharma’s VB100 & VB210 have both displayed they can effectively treat a multitude of illnesses -- and they’ve been demonstrated to be safe and more effective than any other treatments currently available.

You might be shocked at how many of the 10 Keys that VBIO checks off this list, but most importantly, it will help you discover for yourself how to make wise investments in the pharma/biotech niche. Download my ebook below to learn more.

First and BEST to market often dominate.

The rest are just picking up scraps.

Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.

Why are Opioids At risk?

Society has reached a breaking point with the catastrophic effects caused by opioids, and the government has recently acted in an attempt to curb the epidemic. These actions are similar to those of the D.A.R.E. campaign back in the 80s and 90s, except this time it’s combating prescription drugs instead of illicit ones. There’s a big difference here; illicit drugs can’t be regulated, but prescription drugs can.

That means the crackdown isn’t on society as a whole, but it is being implemented on pharmaceutical companies and doctors. Both are scrambling to find a replacement for highly addictive opiates and one new biotech may just be flying under the radar, making its way through clinical trials with the solution.

Vitality Biopharma (OTCQB: VBIO) is on the verge of creating the next generation of chronic pain management drugs, an almost $83 billion market. (1)

How They Do It

Vitality Biopharma (OTCQB: VBIO) has harnessed the therapeutic abilities of cannabinoids derived from marijuana, with its proprietary prodrugs, providing patients with not just pain management, but also treating a wide range of other illnesses. With its proprietary formulations, VBIO has created an entirely new class of cannabinoid (CBD) glycosides, called “cannabosides.” CBD is a naturally occurring compound in marijuana with proven anti-inflammatory, antioxidant, and calming effects, among several other medical benefits.

VBIO is steadily proving CBD to be a game-changing drug throughout ongoing FDA trials—And they’ve came up with their own proprietary formulation that preserves all the beneficial aspects of CBD, without the side-effects of “getting high".

VBIO is a micro-cap CBD pharmaceutical company that sports all of the markings of a blockbuster biotech. Vitality’s pipeline is loaded and their most recent top performers, VB100 and VB210 have already passed a major hurdle in receiving FDA approval during preclinical studies. VBIO has also received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel, which permits the company to scale up activities at its facilities developing novel cannabinoid pharmaceutical prodrugs. This begins the regulatory approval phase for the first-in-man clinical trials this year, allowing VBIO to proceed through their final phase and get to market.

Simply put, the government is no longer holding VBIO back from providing relief to an array of illnesses.

Opiates Are The Past, Cannabinoids Are The Future

CBD has completely changed big pharma’s R&D’s focus the last few years when it comes to pain management. Recently, there has been a huge push in the pharmacological world to address and find a solution to the opioid crisis. 

Currently, the industry has been able to do so with a few CBD formulations, but with limited success. To date, there are three cannabinoid products approved by the U.S. to unlock the therapeutic potential of marijuana, yet IMS health estimates sales have only reached $133 million in 2014, and they haven’t grown much since. So, what’s causing such a lag in sales for these products?

Sales are being suppressed by several things like poor oral bioavailability, irregular metabolism, inconvenient administration, short active response, poor tolerability, and in some cases, psychoactive side effects. In short, these companies weren’t able to formulate their drugs in a way that enabled them to release enough active ingredient (CBD), to be effective or administered through realistic daily-living methods.

VBIO has overcome these challenges with their proprietary cannabosides, developed through modifying CBD by enzymatic glycosylation. These IP-protected compounds tack on glucose to cannabinoids, making them water soluble. VBIO’s prodrugs make their way through the GI tract into the colon, where they are released. These agents coat and cool the intestine, providing pain relief, and relief of inflammation for patients, while limiting the amount of THC released into the bloodstream and brain. This targeted therapy greatly increases the efficacy and efficiency of CBD, maximizing their their deliverability to the mechanism of action,, while eliminating its psychoactive ability.

Vitality’s cannaboside drugs have shown to be nearly 10 times as potent as morphine for neuropathic pain relief, and non addictive. Studies have shown that they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. These and other revelations are the reason why VBIO’s proprietary cannaboside drug therapies are the next generation of chronic pain management.

Big Pharma Shutting The Doors On Opioids

Sweeping regulations this summer caused Purdue Pharma, the biggest opioid producer on the market, to lay off most of its sales force(2) for OxyContin and is steadily downsizing operations. This immediately created an opportunity for R&D teams across the world to find a replacement. With big pharma jumping into the game so late, the answer, like so often in the medical world, probably lies in the hands of a new biotech or pharma startup. Which isn’t that surprising, as startups account for 63% (3) of worldwide prescription drugs currently on the market.

More than 2.4 million Americans suffer from a severe opioid use disorder, which includes dependence on heroin or a prescription opiate drugs. Opioids are involved in 61% of all overdoses across the county and the most recent data from the CDC reports more than 42,000 American deaths (4) occur each year due to opioid overdose.

Given these statistics and seeing no end in sight to the opioid epidemic, it’s no wonder that increased regulations and new oversight protocols are being enforced throughout the country. Certainly, big pharma wasn’t going to, provided prescriptions for painkillers have steadily increased the last 50 years and are a crucial aspect of taking care of our aging population. Because of this increase and the presumed need for these medications, Pharma wasn’t ready for the type of crackdown brought down by the Trump administration. And, following Purdue Pharma’s most recent actions, the industry is starting to talk, asking when alternatives like AbbVie Inc.’s VicodinÒ and Endo International’s PercocetÒ are going to be the next to transition themselves off the opioid market. The fact their time is coming sooner than later is the most likely scenario, provided how far these companies have distanced themselves from their own opioid products.

 SO Much Bigger Than Chronic Pain Management

Vitality Biopharma (VBIO) is setting itself up to be the market leader with its own new proprietary class of prodrugs, producing something truly new and innovative for a long range of illnesses and pain management—something that is bound to totally change the medical world and offer major new solutions for a market in need. With its DEA approval and clinical trials in place, VBIO is ahead of the competitive curve and set to deliver what society has been so eagerly awaiting.

Beyond pain management, VBIO has also shown the ability to treat neurological and inflammatory disorders. The greatest potential, coming from their most recent clinical trials, has provided data showing positive results for patients suffering from the side effects from therapies like inflammatory bowel disease (IBD) & narcotic bowel syndrome (NBS).

Vitality is continuing to see strong efficacy in preclinical results for these “gut-targeted” treatments. In fact, VBIO’s treatment was able to reduce weight loss, damage to the colon, and largely improve gastrointestinal health compared to placebo controls.

Furthermore, the antimicrobial activity that has been demonstrated over time during tests of VBIO's therapies has been found to be so positive that the company has gone as far as filing for patent protection on the use of CBD-derived compounds for the treatment of microbe, including Clostridium difficile and other "superbug" pathogens.

And get this: at the top of the CDC's list is none other than Clostridium difficile (C. diff), which is classified as “an urgent threat to human health.” Why is that so important? Vitality has already demonstrated antimicrobial reactivity of CBD derivatives against C. diff, and is conducting follow-on studies designed to enable pharmaceutical use of their targeted cannabinoid prodrugs for this application.

Studies conducted by VBIO have also shown that its prodrug inhibits colon cancer cell line growth at concentrations that are similar to those used by conventional chemotherapeutics. In the United States in 2017, the American Cancer Society estimated that 50,260 deaths occurred due to colorectal cancer, making it the third-leading cause of cancer-related death for women, and the second-leading cause of cancer-related death for men. If VB100 or 210 is approved to treat colon cancer following their current Phase II trials, this is a huge opportunity for investors.

VBIO’s pipeline is one of the most robust the industry has seen a quite some time, returning positive data for so many applications during FDA trials. Another application that’s recently been tested is VBIO’s proprietary cannabidiol and endocannabinoids, involved in key aspects of neuroprotection and remyelination, a regenerative process in the brain. Vitality’s cannabinoids have shown to be protective of oligodendrocyte progenitor cells, which show to be critical for brain repair in multiple sclerosis (MS). Clinical trial designs are beginning to include cannabosides in combination with approved drugs in order to reverse neurological damage caused by MS.


 Importance of Intellectual Property (IP)

Based on these and other positive results, VBIO is actually seeking broad intellectual property coverage against these pathogens through 2035. This allows VBIO to attain composition of matter claims for prodrugs of THC, CBD, and CBDV, protecting their intellectual property for every significant CBD pharmaceutical in their pipeline.

While we are still on the heels of everyone talking about GW Pharma and how their stock raised from $8/share to $164/share during clinical trials, VBIO is actually in a much stronger position to profit over the long term. Credit to GW Pharma is certainly due; after all, they were the first to gain DEA and FDA approval for their own CBD based drug Epidiolex, which has shown to greatly reduce seizures for patients suffering from epilepsy.

However, GW Pharma may have been in a rush by not obtaining their own IP rights for Epidiolex. GW Pharma is currently the biggest market-cap CBD pharma company, but it’s border-line shocking that it doesn’t even own its compounds! This makes them susceptible to any copy-cat company that is looking to piggy-back off their research and future medicine advancements.

Very few cannabinoid pharma companies are ever going to hold cannabinoid intellectual property, simply because you cannot protect IP for naturally-occurring substances. That’s what makes VBIO so unique and such an incredible investment opportunity. They own all their own compounds and have protected their own IP. They have designed a new class of drugs called cannabosides, and they own all the ‘composition of matter’ behind it.

With everything going for this young biotech startup, VBIO is not satisfied with its recent successes.

Even as news broke of its positive results from Phase I clinical trials and progressing to Phase II, VBIO had simultaneously created more than 200 other cannabinoid compounds and have patent claims for 79 of them!


Investing in VBIO now could be bigger than investing in GW Pharmaceuticals five years ago. At that time, during Phase I and II trials, Epidiolex was showing its ability to reduce seizures for patients suffering from epilepsy. As the first companies to successfully conduct CBD/THC FDA trials with such strong results, both GW Pharma and VBIO are setting themselves up to change the industry for years to come.

A key difference is that VBIO is just about to enter Phase II clinical trials... which is the same stage in which GW Pharma’s stock price skyrocketed.

 How Big Can VBIO Go

This is not one of those pipe-dream “clinical trial Phase I” stock; Vitality (OTCQB:VBIO) is a serious pharmaceutical company. VBIO presents what just might be an investment opportunity of a lifetime. VBIO prodrugs not only have the potential to be a part of the solution to solving the opioid epidemic with safe, effective, and non-addictive pain-relief, but they are also showing industry-changing results treating other major illnesses in clinical trials.

Considering the range of illnesses for which VB100 & VB210 may provide effective treatment (including IBD, MS and pain management markets), there is HUGE potential that VBIO could become a $1 billion company in short time. IBD treatments on the global market are over $6.7 billion per year and growing (5), multiple sclerosis treatments are expected to reach $24 billion per year by 2024 (6), and global opioid sales reaching $23 billion per year (7). This makes for more than a $50 billion opportunity for VBIO. It could provide major revenues for VBIO if they only capture a fragment of these potential markets.

With rising forecasts for the need for painkillers to treat a range of chronic pain issues such as those arising from illnesses like cancer, arthritis and post-surgical operations, painkillers aren’t leaving the market anytime soon. In fact, they’re growing. When the most utilized and known pharma solutions like Purdue Pharma’s OxyContin is showing gaping chips in its armor, doctors and governments are seeking other options in pain management.  

VBIO is taking advantage of its own new proprietary delivery class of prodrugs, producing something truly new and innovative for a long range of illnesses and pain management. This is something that is bound to totally change the medical world and offer major new solutions for a market in need. With its DEA approval and clinical trials in place, VBIO is ahead of the competitive curve and set to deliver what society has been so eagerly awaiting.

How can I be so sure of this? 

 The 10 KEYS for Profitable Pharmaceutical & Biotech Investments

Since the biggest gains have already been made with companies like GW Pharma, I’ve been searching for my next record-breaking medical stock. Throughout my 25-year career of researching and investing, I’ve developed a checklist of qualities I identify in companies EVERY TIME before putting my hard-earned cash behind them. Call it sweat equity if you will, because this system requires a lot of research and time to track the development of potential investment opportunities and how to properly analyze how a company’s pipeline is progressing. 

In order to help others gain this big-picture perspective, I’ve distilled my system and call it the 10 KEYS for Profitable Pharmaceutical & Biotech Investments. I fully cover each of the 10 KEYS in my new ebook.

When applying these 10 KEYS, I immediately knew GW Pharma had discovered a drug with huge market potential. But honestly, this wasn’t rocket science, because medical researchers had known for decades that CBD could be an effective treatment for seizures. However, what was vitally important for me was the timing of my investment and knowing when to divest some of my investment. In the case of GW Pharma, discovering their ceiling had a lot to do with the imprudence on their part of not obtaining IP for their groundbreaking formulations. This decision, like so many other examples, came about by applying the 10-KEYS that have helped me establish a long-term career investing in the stock market, specifically in the pharma/biotech niche. If you’re considering investing in any stock falling within this niche, it is essential that you understand just how important these 10 KEYS are. Frankly, you might know some of the KEYS, but do you have a system to streamline your decision-making strategy?

I’ve spent so much time introducing VBIO and describing just how much incredible potential this company has, simply because they are positioning themselves to corner the market with IP-protected formulations of CBD that also eliminate its psychoactive ability. For years to come, big pharma and blue-chip biotech’s entering the CBD market will most likely have to pay significant royalties or include VBIO in their research in order to produce their own. This is just one of the keys, but it alone can ensure immediate investing gains if timed right and certainty lock in long-term profit.

With the current state of the biotech market, it’s important for investors to familiarize themselves with VBIO right now. I encourage you to read their regulatory filings, press releases and current 2018 prospectus, and you’ll learn what I’ve been researching over the last several weeks.

Apply the 10 KEYS not just to VBIO, but to any pharma/biotech stock you’ve been tracking and you will be ahead of so many others who are about to rush into the market.

The biotech industry has already shown that a massive bull run is underway. What was hype and speculation only a few years ago is now an increasingly investable market with tremendous upside. The future profit center for investors in this industry will be biopharma R&D that is pioneered by companies with proprietary technology and the intellectual property leading to exciting medical breakthroughs. Vitality Biopharma’s VB100 & VB210 have both displayed they can effectively treat a multitude of illnesses -- and they’ve been demonstrated to be safe and more effective than any other treatments currently available.

You might be shocked at how many of the 10 Keys that VBIO checks off this list, but most importantly, it will help you discover for yourself how to make wise investments in the pharma/biotech niche. Download my ebook below to learn more.

First and BEST to market often dominate.

The rest are just picking up scraps.

Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

Start Reading “The Complete Guide to Identifying Record-Breaking Trades”

You’ve taken a GREAT first step towards some amazing trading opportunities and I’m so grateful that you’ve given me the chance to share MY knowledge with YOU!

Daryl Thompson


Learn to Find and Trade The Simple Keys That Record-Breaking Stocks Have In Common For Major Profits

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

Start Reading “The Complete Guide to Identifying Record-Breaking Trades”

You’ve taken a GREAT first step towards some amazing trading opportunities and I’m so grateful that you’ve given me the chance to share MY knowledge with YOU!

Daryl Thompson


Learn to Find and Trade The Simple Keys That Record-Breaking Stocks Have In Common For Major Profits

ADVERTISEMENT DISCLAIMER

THIS REPORT/ADVERTORIAL (“ADVERTORIAL”) IS A PAID COMMERCIAL ADVERTISEMENT AND IS FOR GENERAL INFORMATION PURPOSES ONLY. Neither The Trading Letter nor Daryl Thompson (“Endorser) is making a recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by readers that learn of the profiled companies through this website. This Advertorial was paid for by a non-issuer third party in an effort to enhance public awareness of Vitality BioPharma (VBIO) and its securities. TheTradingLetter.com has or will receive $30,000 in cash in connection with this effort. Endorser has or will receive compensation in the form of leads valued at approximately $1,000 that are expected to result in additional subscription revenue in connection with this effort. Neither TheTradingLetter.com nor Endorser currently holds the securities of VBIO and do not currently intend to purchase such securities. Endorser is solely responsible for and has ultimate authority over the Advertorial and contents of the statements contained in this Advertorial. This Advertorial is based exclusively on information generally available to the public and does not contain any material, non-public information. Neither TheTradingLetter.com nor Endorser warrants the accuracy of such information. Certain statements contained in this Advertorial may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," “expects," "projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Neither TheTradingLetter.com nor Endorser undertakes an obligation to update forward-looking statements in light of new information or future events. Readers can review all public SEC filings made by the featured company at https://www.sec.gov/edgar/searchedgar/companysearch.html.

Neither TheTradingLetter.com nor Endorser are licensed in the securities industry in any manner. Please review all investment decisions with a licensed investment advisor.

Why are Opioids At risk?

Society has reached a breaking point with the catastrophic effects caused by opioids, and the government has recently acted in an attempt to curb the epidemic. These actions are similar to those of the D.A.R.E. campaign back in the 80s and 90s, except this time it’s combating prescription drugs instead of illicit ones. There’s a big difference here; illicit drugs can’t be regulated, but prescription drugs can.

That means the CRACKDOWN isn’t on society as a whole, but it is being implemented on pharmaceutical companies and doctors. Both are scrambling to find a replacement for highly addictive opiates and one new biotech may just be flying under the radar, making its way through clinical trials with the solution.

Vitality Biopharma (OTCQB: VBIO) is on the verge of creating the next generation of chronic pain management drugs, an almost $83 billion market(1).

How They Do It

Vitality Biopharma (VBIO) has harnessed the therapeutic abilities of cannabinoids derived from marijuana, with its proprietary prodrugs, providing patients with not just pain management, but also treating a wide range of other illnesses. With its proprietary formulations, VBIO has created an entirely new class of cannabinoid (CBD) glycosides, called “cannabosides.” CBD is a naturally occurring compound in marijuana with proven anti-inflammatory, antioxidant, and calming effects, among several other medical benefits.

VBIO is steadily proving CBD to be a game-changing drug throughout ongoing FDA trials—And they’ve came up with their own proprietary formulation that preserves all the beneficial aspects of CBD, without the side-effects of “getting high".

VBIO is a micro-cap CBD pharmaceutical company that sports all of the markings of a blockbuster biotech. Vitality’s pipeline is loaded and their most recent top performers, VB100 and VB210 have already passed a major hurdle in receiving FDA approval during preclinical studies. VBIO has also received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of California Research Advisory Panel, which permits the company to scale up activities at its facilities developing novel cannabinoid pharmaceutical prodrugs. This begins the regulatory approval phase for the first-in-man clinical trials this year, allowing VBIO to proceed through their final phase and get to market.

Simply put, the government is no longer holding VBIO back from providing relief to an array of illnesses.

Opiates Are The Past, Cannabinoids Are The Future

CBD has completely changed big pharma’s R&D’s focus the last few years when it comes to pain management. Recently, there has been a huge push in the pharmacological world to address and find a solution to the opioid crisis.

Currently, the industry has been able to do so with a few CBD formulations, but with limited success. To date, there are three cannabinoid products approved by the U.S. to unlock the therapeutic potential of marijuana, yet IMS health estimates sales have only reached $133 million in 2014, and they haven’t grown much since. So, what’s causing such a lag in sales for these products?

Sales are being suppressed by several things like poor oral bioavailability, irregular metabolism, inconvenient administration, short active response, poor tolerability, and in some cases, psychoactive side effects. In short, these companies weren’t able to formulate their drugs in a way that enabled them to release enough active ingredient (CBD), to be effective or administered through realistic daily-living methods.

VBIO has overcome these challenges with their proprietary cannabosides, developed through modifying CBD by enzymatic glycosylation. These IP-protected compounds tack on glucose to cannabinoids, making them water soluble. VBIO’s prodrugs make their way through the GI tract into the colon, where they are released. These agents coat and cool the intestine, providing pain relief, and relief of inflammation for patients, while limiting the amount of THC released into the bloodstream and brain. This targeted therapy greatly increases the efficacy and efficiency of CBD, maximizing their their deliverability to the mechanism of action,, while eliminating its psychoactive ability.

Vitality’s cannaboside drugs have shown to be nearly 10 times as potent as morphine for neuropathic pain relief, and non addictive. Studies have shown that they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. These and other revelations are the reason why VBIO’s proprietary cannaboside drug therapies are the next generation of chronic pain management.

Big Pharma Shutting The Doors On Opioids

Sweeping regulations this summer caused Purdue Pharma, the biggest opioid producer on the market, to lay off most of its sales force(2) for OxyContin and is steadily downsizing operations. This immediately created an opportunity for R&D teams across the world to find a replacement. With big pharma jumping into the game so late, the answer, like so often in the medical world, probably lies in the hands of a new biotech or pharma startup. Which isn’t that surprising, as startups account for 63%(3) of worldwide prescription drugs currently on the market.

More than 2.4 million Americans suffer from a severe opioid use disorder, which includes dependence on heroin or a prescription opiate drugs. Opioids are involved in 61% of all overdoses across the county and the most recent data from the CDC reports more than 42,000 American deaths(4) occur each year due to opioid overdose.

Given these statistics and seeing no end in sight to the opioid epidemic, it’s no wonder that increased regulations and new oversight protocols are being enforced throughout the country. Certainly, big pharma wasn’t going to, provided prescriptions for painkillers have steadily increased the last 50 years and are a crucial aspect of taking care of our aging population. Because of this increase and the presumed need for these medications, Pharma wasn’t ready for the type of crackdown brought down by the Trump administration. And, following Purdue Pharma’s most recent actions, the industry is starting to talk, asking when alternatives like AbbVie Inc.’s VicodinÒ and Endo International’s PercocetÒ are going to be the next to transition themselves off the opioid market. The fact their time is coming sooner than later is the most likely scenario, provided how far these companies have distanced themselves from their own opioid products.

 SO Much Bigger Than Chronic Pain Management

VBIO is setting itself up to be the market leader with its own new proprietary class of prodrugs, producing something truly new and innovative for a long range of illnesses and pain management—something that is bound to totally change the medical world and offer major new solutions for a market in need. With its DEA approval and clinical trials in place, VBIO is ahead of the competitive curve and set to deliver what society has been so eagerly awaiting.

Beyond pain management, VBIO has also shown the ability to treat neurological and inflammatory disorders. The greatest potential, coming from their most recent clinical trials, has provided data showing positive results for patients suffering from the side effects from therapies like inflammatory bowel disease (IBD) & narcotic bowel syndrome (NBS).

Vitality is continuing to see strong efficacy in preclinical results for these “gut-targeted” treatments. In fact, Vitality’s treatment was able to reduce weight loss, damage to the colon, and largely improve gastrointestinal health compared to placebo controls.

Furthermore, the antimicrobial activity that has been demonstrated over time during tests of Vitality’s therapy’s has been found to be so positive that the company has gone as far as filing for patent protection on the use of CBD-derived compounds for the treatment of microbe, including Clostridium difficile and other "superbug" pathogens.

And get this: at the top of the CDC's list is none other than Clostridium difficile (C. diff), which is classified as “an urgent threat to human health.” Why is that so important? Vitality has already demonstrated antimicrobial reactivity of CBD derivatives against C. diff, and is conducting follow-on studies designed to enable pharmaceutical use of their targeted cannabinoid prodrugs for this application.

Studies conducted by Vitality Biopharma (VBIO) have also shown that its prodrug inhibits colon cancer cell line growth at concentrations that are similar to those used by conventional chemotherapeutics. In the United States in 2017, the American Cancer Society estimated that 50,260 deaths occured due to colorectal cancer, making it the third-leading cause of cancer-related death for women, and the second-leading cause of cancer-related death for men. If VBIO 100 or 210 is approved to treat colon cancer following their current Phase II trials, this is a huge opportunity for investors.

VBIO’s pipeline is one of the most robust the industry has seen a quite some time, returning positive data for so many applications during FDA trials. Another application that’s recently been tested is Vitality Biopharma’s proprietary cannabidiol and endocannabinoids, involved in key aspects of neuroprotection and remyelination, a regenerative process in the brain. Vitality’s cannabinoids have shown to be protective of oligodendrocyte progenitor cells, which show to be critical for brain repair in multiple sclerosis (MS). Clinical trial designs are beginning to include cannabosides in combination with approved drugs in order to reverse neurological damage caused by MS.


 Importance of Intellectual Property (IP)

Based on these and other positive results, Vitality is actually seeking broad intellectual property coverage against these pathogens through 2035. This allows VBIO to attain composition of matter claims for prodrugs of THC, CBD, and CBDV, protecting their intellectual property for every significant CBD pharmaceutical in their pipeline.

While we are still on the heels of everyone talking about GW Pharma and how their stock raised from $8/share to $164/share during clinical trials, VBIO is actually in a much stronger position to profit over the long term. Credit to GW Pharma is certainly due; after all, they were the first to gain DEA and FDA approval for their own CBD based drug Epidiolex, which has shown to greatly reduce seizures for patients suffering from epilepsy.

However, GW Pharma may have been in a rush by not obtaining their own IP rights for Epidiolex. GW Pharma is currently the biggest market-cap CBD pharma company, but it’s border-line shocking that it doesn’t even own its compounds! This makes them susceptible to any copy-cat company that is looking to piggy-back off their research and future medicine advancements.

Very few cannabinoid pharma companies are ever going to hold cannabinoid intellectual property, simply because you cannot protect IP for naturally-occurring substances. That’s what makes VBIO so unique and such an incredible investment opportunity. They own all their own compounds and have protected their own IP. They have designed a new class of drugs called cannabosides, and they own all the ‘composition of matter’ behind it.

With everything going for this young biotech startup, VBIO is not satisfied with its recent successes.

Even as news broke of its positive results from Phase I clinical trials and progressing to Phase II, VBIO had simultaneously created more than 200 other cannabinoid compounds and have patent claims for 79 of them!

Investing in VBIO now could be bigger than investing in GW Pharmaceuticals five years ago. At that time, during Phase I and II trials, Epidiolex was showing its ability to reduce seizures for patients suffering from epilepsy. As the first companies to successfully conduct CBD/THC FDA trials with such strong results, both GW Pharma and VBIO are setting themselves up to change the industry for years to come.

A key difference is that VBIO is just about to enter Phase II clinical trials... which is the same stage in which GW Pharma’s stock price skyrocketed.

 How Big Can VBIO Go

This is not one of those pipe-dream “clinical trial Phase I” stock; Vitality (OTCQB:VBIO) is a serious pharmaceutical company. VBIO presents what just might be an investment opportunity of a lifetime. Vitality prodrugs not only have the potential to be a part of the solution to solving the opioid epidemic with safe, effective, and non-addictive pain-relief, but they are also showing industry-changing results treating other major illnesses in clinical trials.

Considering the range of illnesses for which VB100 & VB210 may provide effective treatment (including IBD, MS and pain management markets), there is HUGE potential that VBIO could become a $1 billion company in short time. IBD treatments on the global market are over $6.7 billion per year and growing(5), multiple sclerosis treatments are expected to reach $24 billion per year by 2024(6), and global opioid sales reaching $23 billion per year(7). This makes for more than a $50 billion opportunity for Vitality Biopharma. It could provide major revenues for VBIO if they only capture a fragment of these potential markets.

With rising forecasts for the need for painkillers to treat a range of chronic pain issues such as those arising from illnesses like cancer, arthritis and post-surgical operations, painkillers aren’t leaving the market anytime soon. In fact, they’re growing. When the most utilized and known pharma solutions like Purdue Pharma’s OxyContin is showing gaping chips in its armor, doctors and governments are seeking other options in pain management.  

VBIO is taking advantage of its own new proprietary delivery class of prodrugs, producing something truly new and innovative for a long range of illnesses and pain management. This is something that is bound to totally change the medical world and offer major new solutions for a market in need. With its DEA approval and clinical trials in place, VBIO is ahead of the competitive curve and set to deliver what society has been so eagerly awaiting.

How can I be so sure of this? 

 The 10 KEYS for Profitable Pharmaceutical & Biotech Investments

Since the biggest gains have already been made with companies like GW Pharma, I’ve been searching for my next record-breaking medical stock. Throughout my 25-year career of researching and investing, I’ve developed a checklist of qualities I identify in companies EVERY TIME before putting my hard-earned cash behind them. Call it sweat equity if you will, because this system requires a lot of research and time to track the development of potential investment opportunities and how to properly analyze how a company’s pipeline is progressing.

In order to help others gain this big-picture perspective, I’ve distilled my system and call it the 10 KEYS for Profitable Pharmaceutical & Biotech Investments. I fully cover each of the 10 KEYS in my new ebook.

When applying these 10 KEYS, I immediately knew GW Pharma had discovered a drug with huge market potential. But honestly, this wasn’t rocket science, because medical researchers had known for decades that CBD could be an effective treatment for seizures. However, what was vitally important for me was the timing of my investment and knowing when to divest some of my investment. In the case of GW Pharma, discovering their ceiling had a lot to do with the imprudence on their part of not obtaining IP for their groundbreaking formulations.

This decision, like so many other examples, came about by applying the 10-KEYS that have helped me establish a long-term career investing in the stock market, specifically in the pharma/biotech niche. If you’re considering investing in any stock falling within this niche, it is essential that you understand just how important these 10 KEYS are. Frankly, you might know some of the KEYS, but do you have a system to streamline your decision-making strategy?

I’ve spent so much time introducing VBIO and describing just how much incredible potential this company has, simply because they are positioning themselves to corner the market with IP-protected formulations of CBD that also eliminate its psychoactive ability. For years to come, big pharma and blue-chip biotech’s entering the CBD market will most likely have to pay significant royalties or include VBIO in their research in order to produce their own. This is just one of the keys, but it alone can ensure immediate investing gains if timed right and certainty lock in long-term profit.

With the current state of the biotech market, it’s important for investors to familiarize themselves with VBIO right now. I encourage you to read their regulatory filings, press releases and current 2018 prospectus, and you’ll learn what I’ve been researching over the last several weeks.

Apply the 10 KEYS not just to VBIO, but to any pharma/biotech stock you’ve been tracking and you will be ahead of so many others who are about to rush into the market.

The biotech industry has already shown that a massive bull run is underway. What was hype and speculation only a few years ago is now an increasingly investable market with tremendous upside. The future profit center for investors in this industry will be biopharma R&D that is pioneered by companies with proprietary technology and the intellectual property leading to exciting medical breakthroughs. Vitality Biopharma’s VB100 & VB210 have both displayed they can effectively treat a multitude of illnesses -- and they’ve been demonstrated to be safe and more effective than any other treatments currently available.

You might be shocked at how many of the 10 Keys that VBIO checks off this list, but most importantly, it will help you discover for yourself how to make wise investments in the pharma/biotech niche subscribe.

First and BEST to market often dominate.

The rest are just picking up scraps.


Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.

Thank You! Your Ebook Is READY!

Start Reading “The Complete Guide to Identifying Record-Breaking Trades”

You’ve taken a GREAT first step towards some amazing trading opportunities and I’m so grateful that you’ve given me the chance to share MY knowledge with YOU!

Daryl Thompson

P.S. I just published my latest white paper that I’d like to share with you...it’s below and it’s eye opening.

Learn to Find and Trade The Simple Keys That Record-Breaking Stocks Have In Common For Major Profits